1. The invention is (I) a derivative of pyridine pyridine, which conforms to the formula of (I), wherein R1 is a hydrogen atom or a hydrocarbon (C1-C4)；R2 represents a population - (CH2) n '- B where n' = 0, 1, 2, 3 or 4 and B represents a cyclopentyl (C3-C5),1. One asphalt group (C1-C4) or one alcox group (C1-C4)；Y. Z, V and W represent an independent groupIt should be understood that a cycle including V, W, y and Z is a cycle with five to six links, but it is understood that the discrete line of the cycle indicates that the generated cycle is an aromatic cycle, and the cycle is understood to include zero links, One or two heteroatoms；R3 and R4 represent independent,Same or different groups, selected from hydrogen atoms；1. A group of linear tar (C1-C4) or a group of unidirectional tar (C3-C5) formed with carbon；M integer is equal to 1, 2, 3 or 4；R5 represents hydrogen atom or tar group (C1-C4)；R6 represents an n-l group, n = 0, 1, 2 or 3, and l is a group selected from arilos of six carbon atoms, which are heterogeneous of five to six carbon atoms, heterogeneous saturation cycle composed of five, six or seven carbon atoms, or formed together with nitrogen atoms and connected with a heterogeneous group, (II) prepare and (III) use for therapeutic purposes to inhibit kunsa activity in PDGFs alliance recipients and / or FLT3 alliance recipients.La invención se refiere (i) a derivados de piridino-piridinonas que responden a la fórmula (I) : en la que R1 representa un átomo de hidrógeno o un grupo alquilo(C1-C4) ； R2 representa un grupo -(CH2)n'-B donde n'=0, 1, 2, 3 o 4 y B representa un grupo cicloalquilo(C3-C5), un grupo alquilo(C1-C4) o un grupo alcoxi(C1-C4) ； Y, Z, V y W representan, independientemente entre sí un grupo -CH-, un átomo de carbono, un heteroátomo o ausencia de átomo, entendiéndose que el ciclo, en el que están comprendidos V, W, Y y Z es un ciclo que comprende 5 o 6 eslabones, entendiéndose que las líneas discontinuas en dicho ciclo indican que el
